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Background: L-carnitine supplementation has been associated with a significant reduction in all-cause mortality,
ventricular arrhythmia, and angina in the setting of acute myocardial infarction (MI). However, on account of strict
homeostatic regulation of plasma L-carnitine concentrations, higher doses of L-carnitine supplementation may not
provide additional therapeutic benefits. This study aims to evaluate the effects of various oral maintenance dosages
of L-carnitine on all-cause mortality and cardiovascular morbidities in the setting of acute MI.
Methods: After a systematic review of several major electronic databases (PubMed, EMBASE, and the Cochrane
Library) up to November 2013, a meta-analysis of five controlled trials (n = 3108) was conducted to determine the
effects of L-carnitine on all-cause mortality and cardiovascular morbidities in the setting of acute MI.
Results: The interaction test yielded no significant differences between the effects of the four daily oral maintenance
dosages of L-carnitine (i.e., 2 g, 3 g, 4 g, and 6 g) on all-cause mortality (risk ratio [RR] = 0.77, 95% CI [0.57-1.03], P = 0.08)
with a statistically insignificant trend favoring the 3 g dose (RR = 0.48) over the lower 2 g dose (RR = 0.62), which was
favored over the higher 4 g and 6 g doses (RR = 0.78, 0.78). There was no significant differences between the effects of
the daily oral maintenance dosages of 2 g and 6 g on heart failure (RR = 0.53, 95% CI [0.25-1.13], P = 0.10), unstable
angina (RR = 0.90, 95% CI [0.51-1.58], P = 0.71), or myocardial reinfarction (RR = 0.74, 95% CI [0.30-1.80], P = 0.50).
Conclusions: There appears to be no significant marginal benefit in terms of all-cause mortality, heart failure, unstable
angina, or myocardial reinfarction in the setting of acute MI for oral L-carnitine maintenance doses of greater or less
than 3 g per day.
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Cardiovasular disease (CVD) is the world's leading cause of
death, far outstripping infectious disease mortality from
malaria, HIV/AIDS, and tuberculosis [1]. In the U.S., CVD
is the leading cause of death, constitutes 17% of healthcare
costs, and is estimated to increase in prevalence by ~10%
and direct costs by almost three-fold over the next 20 years
under current CVD prevention and treatment regimes [2].
However, secondary preventative interventions such as
antiplatelet drugs, β-blockers, angiotensin-converting-
enzyme (ACE) inhibitors, angiotensin-receptor blockers* Correspondence: srp0459@163.com
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unless otherwise stated.(ARBs), and HMG-CoA reductase inhibitors (statins) have
been shown to significantly reduce CVD risk [3]. There-
fore, a greater focus on improving the secondary preven-
tion of CVD should ameliorate these dire projections.
One promising alternative therapy for the secondary
prevention of CVD is L-carnitine, the biologically active
stereoisomer of dietary carnitine (β-hydroxy-γ-N-
trimethylaminobutyric acid) [4]. Cardiac muscle cells
cannot synthesize L-carnitine de novo and must ac-
quire L-carnitine exogenously via the arnitine/organic
cation transporter 2 (OCTN2). Cardiac mitochondria
use the carnitine-acylcarnitine carrier (CAC) to import
fatty acyl moieties for β-oxidation, the primary energy
source in heart muscle [4]. Thus, deficiencies in L-
carnitine or its transporter CAC have particularlyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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myopathy, cardiac arrhythmia, cardiac insufficiency,
and heart failure [4].
As exogenous L-carnitine aids in resumption of nor-
mal oxidative metabolism and restoration of myocar-
dial energy reserves, L-carnitine supplementation has
been shown to have favorable effects in CVD patients [4].
In chronic heart disease patients, L-carnitine administra-
tion over 12 months has been shown to attenuate left
ventricular dilatation and prevent ventricular remodel-
ing while reducing incidence of chronic heart failure
and death. The protective effects of L-carnitine supple-
mentation also extend to acute myocardial infarction
(MI); following acute MI, prompt L-carnitine adminis-
tration and subsequent oral maintenance therapy has been
shown to attenuate progressive left ventricular dilatation
and appears to reduce myocardial injury through im-
proving carbohydrate metabolism and reducing the
toxicity of high free fatty acid levels [5,6]. A recent sys-
tematic review and meta-analysis of 13 controlled trials
by DiNicolantonio et al. found that L-carnitine supple-
mentation was associated with a significant reduction in
all-cause mortality, ventricular arrhythmia, and angina
in the setting of acute MI [7].
However, the DiNicolantonio's study did not examine
the effect of varying L-carnitine dosing on all-cause
mortality or adverse cardiovasular outcomes. Following
ingestion of a dietary L-carnitine, the rate of L-carnitine
excretion increases rapidly because absolute reabsorp-
tion – which is based on the number of the OCTN2
transporters in the distal tubules of the kidney – does
not change [8]. As L-carnitine levels do not significantly
influence OCTN2 expression, renal filtration maintains
a narrow plasma concentration range of 40–60 μmol/l
with plasma L-carnitine above this threshold being
eliminated via urine [8].
Therefore, on account of this strict homeostatic regu-
lation of plasma L-carnitine concentrations, high doses
of L-carnitine supplementation may not provide add-
itional therapeutic benefits. In this systematic review
and meta-analysis, we aim to determine the effects of
various oral maintenance dosages of L-carnitine on
all-cause mortality and cardiovascular morbidities in
the setting of acute MI.
Methods
Ethics statement
The Ethics Committee (IRB) of Oilfield General Hospital
(Daqing City, Heilong Jiang Province, China) recog-
nizes that this systematic review and meta-analysis of
de-identified, publicly available data does not consti-
tute “human subjects research” as defined by relevant
national regulations, and therefore does not require
Ethics Committee review.Search strategy
A systematic review of the available literature was per-
formed according to the PRISMA (preferred reporting
items for systematic reviews and meta-analyses) guide-
lines for the conduct of systematic reviews of interven-
tion studies [9]. Relevant randomized controlled trials
(RCTs) were identified from systematic searches of sev-
eral major electronic databases (PubMed, EMBASE,
and the Cochrane Library) up to November 2013 with the
following search strategy: (“L-carnitine” OR “carnitine”)
AND “myocardial infarction”. English language and
human study restrictions were imposed in all searches.
Additional relevant articles were obtained through
scanning reference lists of articles identified in the ini-
tial searches.
Inclusion criteria
Studies were selected for inclusion on the basis of the
following criteria: comparative trials of adults (> =
18 years old) receiving oral L-carnitine compared with
placebo or control, with outcomes of all-cause mortality
and adverse cardiovascular events including unstable
angina, myocardial reinfarction, heart failure, and ven-
tricular arrythmia. We excluded studies that did not
report mortality or morbidity outcomes.
Study selection and data extraction
The titles and abstracts of studies identified by the
search strategy were independently screened by two
reviewers, and irrelevant studies were excluded. The
full texts were obtained from all articles meeting the
inclusion criteria. Then, articles were scanned and the data
from these studies was extracted, including the number of
patients per arm, L-carnitine dosing (including initial load-
ing dosing and daily oral maintenance dosing), acute MI
(AMI) index event type, follow-up duration, and outcomes
(i.e., all-cause mortality, adverse cardiovascular events
including unstable angina, acute MI, heart failure, and
ventricular arrythmia). Data extraction was performed
by two independent reviewers.
Quality assessment
Quality assessment was based on the following criteria –
concealment of treatment allocation; similarity of both
groups at baseline regarding prognostic factors and
medication use; blinding of outcome assessors, care pro-
viders, and patients; completeness of follow-up; and
intention-to-treat analysis – and quantified using the
Jadad score [10]. Quality assessment was undertaken by
two independent reviewers. Risk of bias was assessed
using Cochrane Collaboration criteria specifically evalu-
ating sequence generation of allocation; allocation con-
cealment; blinding of participants, staff, and outcome
assessors; incomplete outcome data; selective outcome
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unclear risk of bias in the first three criteria were
deemed ‘high risk’.
Statistical analysis
The meta-analysis of comparable data was performed
using Review Manager 5.0.2 (the Nordic Cochrane
Centre, the Cochrane Collaboration, 2008). For con-
tinuous outcomes, the results were expressed as the
mean difference with a 95% confidence interval (CI).
The degree of heterogeneity across the results of different
studies was quantitatively assessed by the I2 statistic, with
I2 < 30% indicating low heterogeneity, I2 = 30-50% indi-
cating moderate heterogeneity, and I2 > 50% indicating
substantial heterogeneity [11]. In the event of no con-
spicuous heterogeneity, a fixed-effects model was used.
If heterogeneity was detected, a random-effects model
was used. A P < 0.05 was deemed to be statistically sig-
nificant for all analyses.
Results
Study selection and characteristics
The literature search yielded 135 records (Figure 1). After
screening titles and abstracts, only nine studies were eli-
gible for full-text review, of which five met all inclusion
criteria [12-16]. Table 1 summarizes the characteristics ofFigure 1 Flow diagram of literature search.the included studies including their risk of bias. All in-
cluded trials were comparison trials of oral L-carnitine
against placebo or control in the setting of acute MI.
All background medications and baseline characteris-
tics were statistically similar between the comparison
groups in each trial.Quality assessment
Table 2 summarizes the quality indicators of the in-
cluded trials. All five studies scored well on the meth-
odological quality indicators.Study outcomes
All five trials (n = 3108) reported on all-cause mortality
(Figure 2). The interaction test yielded no significant
differences between the effects of the four daily main-
tenance dosages of L-carnitine (i.e., 2 g, 3 g, 4 g, and 6 g)
on all-cause mortality (RR = 0.77, 95% CI [0.57-1.03],
P = 0.08) (Figure 2). Analysis of the all-cause mortality
risk ratios for each dosage yielded a statistically insig-
nificant trend favoring the 3 g dose (RR = 0.48) over
the lower 2 g dose (RR = 0.62), which was favored over
the higher 4 g and 6 g doses (RR = 0.78, 0.78). There
was low heterogeneity between trials for all-cause mor-
tality (I2 = 22%).
Table 1 Characteristics of included studies










Davini 1992 81 79 AMI None 4 g/day Death ◘◘◘
Iliceto 1995 233 239 AMI 9 g/day × 5 days
(intravenous)




Singh 1996 51 50 100% STEMI None 2 g/day Death, heart failure, unstable
angina, reinfarction
◘◘○
Iyer 1999 23 23 Anterior AMI 6 g/day × 7 days (oral) 3 g/day Death ◘◘◘
Tarantini 2006 1168 1161 100% STEMI 9 g/day × 5 days
(intravenous)
4 g/day Death ○○○
†Risk of bias assessment based on (i) sequence generation of allocation, (ii) allocation concealment, and (iii) blinding. The symbol ○ represents low bias risk,
● represents high bias risk, and ◘ represents unclear bias risk.
Abbreviations: AMI acute myocardial infarction, STEMI ST segment elevation myocardial infarction.
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(n = 101), reported on outcomes of heart failure, unstable
angina, and myocardial reinfarction (Figure 3). There was
no significant differences between the effects of the daily
oral maintenance dosages of 2 g and 6 g on heart failure
(RR = 0.53, 95% CI [0.25-1.13], P = 0.10), unstable angina
(RR = 0.90, 95% CI [0.51-1.58], P = 0.71), or myocardial
reinfarction (RR = 0.74, 95% CI [0.30-1.80], P = 0.50]
(Figure 3). There was no heterogeneity between the two
trials for all three outcomes (I2 = 0%).
Discussion
Although L-carnitine supplementation has been associated
with a significant reduction in all-cause mortality, ven-
tricular arrhythmia, and angina in the setting of acute MI
[7], this systematic review and meta-analysis of five con-
trolled trials (n = 3108) found that there is no significant
marginal benefit in terms of all-cause mortality, heart fail-
ure, unstable angina, or myocardial reinfarction for oral
L-carnitine maintenance doses of greater than two grams
per day. However, analysis of the all-cause mortality risk
ratios for each dosage yielded a statistically insignificant
trend favoring the 3 g dose over the lower 2 g dose, which
was favored over the higher 4 g and 6 g doses. Although a
statistically insignificant trend, this profile creates a bell-
shaped curve with the 3 g dose as the optimal dosage in










Davini 1992 1 No No Yes
Iliceto 1995 4 Yes Yes Yes
Singh 1996 3 Yes No Yes
Iyer 1999 5 Yes Yes Yes
Tarantini 2006 3 Yes Yes Yes
N/p = Not provided.The human body's carnitine pool, consisting of free
L-carnitine and its esters, is maintained by (i) absorp-
tion of L-carnitine from dietary sources, (ii) endogenous
biosynthesis from two essential amino acids (lysine and
methionine) in the kidney, liver and brain, and (iii) exten-
sive renal tubular reabsorption (98-99%) from glomerular
filtrate [17]. The absorption of oral L-carnitine occurs via
both passive diffusion and carrier-mediated transport,
which ensures high tissue-to-plasma concentration ratios
in tissues that depend critically on fatty acid oxidation.
The bioavailability from conventional oral supplements
(one to six grams) ranges from a mere 5-18% [17]. One
reason for this low bioavailability is a significant propor-
tion of L-carnitine supplementation is metabolized by
microbiota prior to absorption [18,19]. Human microbiota
are responsible for converting L-carnitine and other
dietary quaternary amines (e.g., choline, glycine betaine,
and phosphatidylcholine) to trimethylamine (TMA),
which are subsequently oxidized by host hepatic flavin
monooxygenases to trimethylamine N-oxide (TMAO),
a molecule that promotes atherogenesis through its
interaction with macrophages and lipid metabolism
[20,21]. Thus, gut microbiota may not only reduce L-
carnitine bioavilability but also promote TMAO-induced
atherosclerotic risk. Interestingly, this limited bioavaila
bility of oral L-carnitine supplements may have been a






No No No Yes No
Yes Yes Yes Yes No
N/p Yes Yes Yes No
Yes Yes Yes No No
N/p Yes Yes Yes Yes
Figure 2 Forest plot of risk ratios for all-cause mortality.
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biome profiles and L-carnitine bioavailability were not
reported in the studies included in this meta-analysis,
future studies should measure these variables when
assessing the efficacy and dosing of L-carnitine in CVD
patients, as certain gut microbiota species (e.g., Gam-
maproteobacteria, Betaproteobacteria, and Firmicutes,
including Acinetobacter species) [22] can display a par-
ticularly adverse influence on the bioavailability of
L-carnitine supplementation as well as atherosclerotic
risk through TMA production.
As the vast majority (>95%) of the human body's carni-
tine pool is located in skeletal muscle, the dynamics of
skeletal muscle carnitine may influence the metabolism of
L-carnitine supplementation. In humans, increased plasmaFigure 3 Forest plot of risk ratios for heart failure, unstable angina, aconcentrations have not been conclusively associated with
an increase in the skeletal muscle carnitine pool [23]. This
phenomenon may be due to saturation of L-carnitine
transport into skeletal muscle at physiological L-carnitine
plasma concentrations (40–60 μmol/l) and/or by the sig-
nificantly higher carnitine concentration in skeletal muscle
relative to plasma, rendering passive transport impossible
[24]. However, other human studies have found opposing
results. Studies providing month-long oral supplementa-
tion of 2 g of L-carnitine per day to long-distance runners
(which consume large amounts of carbohydrates for
training) showed a ~10% increase in skeletal muscle
carnitine content [25,26]. Moreover, recent studies by
Stephens and Wall providing human subjects with twice
daily 1.36 g L-carnitine in combination with a beveragend myocardial reinfarction.
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in skeletal muscle carnitine content over a 12-week period
and a 30% increase in skeletal muscle carnitine content
over a 24-week period [27,28]. These discrepancies may be
explained by the hypothesis that L-carnitine supplementa-
tion accompanied by high amounts of carbohydrate intake
increases skeletal muscle OCTN2 expression through
an insulin-mediated mechanism, thereby increasing
skeletal muscle carnitine content [28,29]. Although
skeletal muscle carnitine content and carbohydrate
intake were not reported in the studies included in this
meta-analysis, future studies should measure these
variables when assessing the efficacy and dosing of L-
carnitine in CVD patients, as these factors may influence
the in vivo metabolism of L-carnitine supplementation.
Although previous studies have shown L-carnitine to
have cardioprotective effects [4-7], recent studies have
also shown that derivatives of L-carnitine may have
adverse consequences on cardiovacular health. As dis-
cussed earlier, Koeth et al.'s study on gut microbiota-
induced TMAO in stable patients undergoing cardiac
evaluation showed significant dose-dependent associa-
tions between plasma L-carnitine levels and risks of
coronary artery disease, peripheral artery disease, and
overall CVD after correction for common CVD risk
factors [18]. Moreover, the same study demonstrated
that elevated fasting plasma L-carnitine levels are an
independent predictor of major adverse cardiac events
after correction for common CVD risk factors [18]. In
another recent clinical study, higher plasma levels of
the L-carnitine derivates acetylcarnitine and palmitoyl-
carnitine have been associated with higher degrees of
heart failure, and higher plasma levels of palmitoyl
carnitine have been associated with higher rates of
all-cause mortality and heart transplantation [30]. As
these recent studies show that higher oral doses of
L-carnitine can promote atherogenesis and CVD risk,
these findings also support our contention of limiting
the oral maintenance dosing of L-carnitine to 3 g per
day in the setting of acute MI and call for further
investigation on the long-term risks of chronic L-
carnitine supplementation in CVD patients.
Several limitations to this study should be noted here.
First, three of the five trials included in the meta-
analysis possessed a relatively small number of patients
(n < 200) – the two large trials, Iliceto 1995 (n = 472)
and Tarantini 2006 (n = 2329), contributed 87% of the
mortality events. However, we found low heterogeneity
between the five trials in all-cause mortality (I2 = 22%)
(Figure 2) and detected no heterogeneity between the
two trials reporting heart failure (I2 = 0%), unstable an-
gina (I2 = 0%), and myocardial reinfarction (I2 = 0%)
(Figure 3). Second, due to lack of reported data, we
could not analyze L-carnitine dosing in the secondaryprevention of ventricular arrythmia in the setting of
acute MI. Third, all included studies were conducted
prior to 2006; as standard treatment regimens for acute
MI patients have changed substantially since then (e.g.,
revascularization with dual antiplatelet therapy, HMG
CoA reductase inhibitors), the potential benefits of
L-carnitine will need to be reassessed in the context of
current treatment regimens that may affect the pharma-
cokinetics of L-carnitine. Fourth, only the effects of the
four daily oral maintenance dosages (2 g, 3 g, 4 g, and
6 g) were analyzed here. Therefore, we could not ascer-
tain whether daily oral maintenance doses under 2 g or
above 6 g are equally effective, nor did we examine the
effects of different initial loading administrations. Fifth,
due to lack of reported data, we could not analyze the
dietary patterns, medication usage, gut microbiome
profiles, L-carnitine bioavailability, or skeletal muscle
carnitine content of the patients included in this meta-
analysis, which may have had differential effects on the
metabolism of L-carnitine. Sixth, the follow-up periods
of the included trials were relatively short-term (one to
twelve months); therefore, interpretation of these find-
ings are restricted to shorter-term outcomes. Seventh,
these results should not be applied to patients with pri-
mary carnitine deficiency (typically arising from genetic
alterations in renal handling or muscle transport of
L-carnitine) or secondary carnitine deficiency (typically
arising from impaired renal tubular resorption from drug
toxicity or hemodialysis). Other studies have analyzed the
pharmacokinetics and provided dosing recommendations
regarding L-carnitine in these patients [31,32].
Conclusions
There appears to be no significant marginal benefit in
terms of all-cause mortality, heart failure, unstable
angina, or myocardial reinfarction in the setting of
acute MI for oral L-carnitine maintenance doses of
greater or less than 3 g per day.
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